Related Experiment Video

Updated: Aug 7, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies

Ryo Honda1,2

  • 1United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.

Cancer Science
|August 6, 2026
PubMed

Insights

Daraxonrasib shows promise in treating pancreatic cancer by targeting multiple RAS proteins. This pan-RAS inhibitor improves survival but faces challenges like toxicity and resistance, prompting research into new strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • RAS proteins are challenging cancer targets, but recent inhibitors show clinical tractability.
  • Daraxonrasib (RMC-6236) is an oral pan-RAS inhibitor targeting multiple RAS variants.
  • Metastatic pancreatic ductal adenocarcinoma (PDAC) remains a significant unmet medical need.

Purpose of the Study:

  • To review the mechanistic and clinical development of daraxonrasib.
  • To examine emerging strategies for improving RAS suppression in cancer therapy.
  • To discuss the therapeutic window and challenges of pan-RAS inhibition.

Main Methods:

  • Review of mechanistic and clinical data for daraxonrasib.
  • Analysis of the RASolute 302 randomized phase III trial.
  • Exploration of emerging therapeutic strategies targeting RAS.

Main Results:

  • Daraxonrasib demonstrated improved survival over chemotherapy in metastatic PDAC.
  • Manageable toxicity was observed, establishing a therapeutic window for pan-RAS inhibition.
  • Challenges include epithelial toxicity and acquired resistance mechanisms.

Conclusions:

  • Daraxonrasib represents a clinically useful pan-RAS inhibitor for PDAC.
  • Future strategies aim to enhance the depth, durability, and selectivity of RAS suppression.
  • New approaches may reshape treatment for RAS-driven cancers.
Keywords:
DaraxonrasibRAS proteinsdrug resistancemolecular targeted therapyneoplasmpan‐RAS inhibition

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...